ClariVest Asset Management’s Sage Therapeutics SAGE Stock Holding History

ClariVest Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,078	Closed	-$662K	–	835
2023 Q2	$662K	Sell	14,078 -2,797	-17%	-$139K	0.03%	316
2023 Q1	$708K	Sell	16,875 -16	-0.1%	-$688	0.03%	332
2022 Q4	$644K	Sell	16,891 -65	-0.4%	-$2.48K	0.03%	351
2022 Q3	$664K	Sell	16,956 -5,344	-24%	-$207K	0.03%	319
2022 Q2	$720K	Sell	22,300 -5,800	-21%	-$194K	0.03%	328
2022 Q1	$930K	Hold	28,100	–	–	0.04%	293
2021 Q4	$1.2M	Sell	28,100 -2,800	-9%	-$117K	0.04%	295
2021 Q3	$1.37M	Sell	30,900 -1,600	-5%	-$73.4K	0.04%	276
2021 Q2	$1.85M	Buy	+32,500	New	+$2.3M	0.06%	221
2018 Q2	–	Sell	-5,240	Closed	-$845K	–	770
2018 Q1	$845K	Buy	5,240 +100	+2%	+$17K	0.01%	448
2017 Q4	$846K	Buy	+5,140	New	+$498K	0.01%	439

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClariVest Asset Management's SAGE Position: Q3 2023 in Review

ClariVest Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 14,078 shares — an estimated $662K sold.

ClariVest Asset Management first reported a position in SAGE in Q4 2017 and held it in 11 quarters. The position peaked at $1.85M in Q2 2021. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

ClariVest Asset Management reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
ClariVest Asset Management sold 14,078 Sage Therapeutics shares in Q3 2023, an estimated $662K.
ClariVest Asset Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 11 quarters.
ClariVest Asset Management's Sage Therapeutics position peaked at $1.85M in Q2 2021.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on ClariVest Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.